Moreover, we identified hypersensitivity to MEK inhibition as a novel collateral sensitivity specific to NF1 loss, which may represent a clinically actionable therapeutic strategy for ALK-inhibitor resistant neuroblastoma. Here, ALK is linked to neuroblastoma.